CD14 and Other metabolic disease: Upon binding to the complex of CD14 and toll-like receptor 4 on the surface of innate immune cells, LPS can induce systemic inflammation, which eventually impairs insulin sensitivity and induces insulin resistance-related metabolic disorders [7].